Sigyn Therapeutics effects 1-for-40 reverse stock split effective Jan 31, 2024

Sigyn Therapeutics, Inc.

Reverse stock split ratio of 1-for-40 effective 12:01 a.m. ET on January 31, 2024.
Post-split shares outstanding ~1,221,043; pre-split shares were ~48.8 million.
No fractional shares; holders rounding up to next whole share automatically.
All outstanding equity awards and warrants proportionately adjusted for the split ratio.
New CUSIP number is 82674U 205; trading symbol remains SIGY.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Sigyn Therapeutics, Inc.: Filing of Certificate of Amendment to Amended and Restated Certificate of Incorporation to effect a 1-for-40 reverse stock split, effective January 31, 2024 (effective 2024-01-31).

Change: charter amendment
Effective: 2024-01-31

Exact text from the filing

On January 23, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) effecting a reverse stock split as of 12:01 a.m. Eastern Standard Time on January 31, 2024 with a ratio of 1-for-40 (the “Reverse Split”).

View on SEC.gov

Browse all governance changes →

Sigyn Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-004320

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.